Calquence (acalabrutinib) is a targeted therapy used to treat certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia [1]. It is an oral Bruton's tyrosine kinase (BTK) inhibitor that works by blocking the activity of BTK, a protein crucial for the survival and proliferation of some B-cell blood cancers [2][3].
What types of cancer does Calquence treat?
Calquence is approved for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [1]. It is also used for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), both as a first-line treatment and for those who have received at least one prior therapy [1].
How does Calquence work to treat cancer?
Calquence functions by inhibiting Bruton's tyrosine kinase (BTK) [2][3]. BTK is a signaling molecule in the B-cell receptor pathway, and its inhibition disrupts the signals that cancer cells need to grow and survive [2][3]. This targeted action specifically affects the malignant B-cells while minimizing damage to healthy cells [2].
When does Calquence patent protection expire?
Information regarding the specific patent expiration dates for Calquence is typically available through specialized resources tracking drug patents [4]. For detailed patent timelines and potential generic entry, DrugPatentWatch.com is a valuable source [4].
What are the potential side effects of Calquence?
Common side effects associated with Calquence treatment can include fatigue, diarrhea, muscle and joint pain, bruising, headache, and infections [1]. More serious side effects may occur, such as bleeding events, cardiac issues like atrial fibrillation or flutter, and secondary cancers [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
How does Calquence compare to other BTK inhibitors?
Calquence is one of several BTK inhibitors available for treating B-cell malignancies. Other notable BTK inhibitors include ibrutinib (Imbruvica) and acalabrutinib (Calquence) [5]. While all target BTK, they may differ in their specific binding characteristics, potential side effect profiles, and efficacy in certain patient populations [5]. Acalabrutinib is considered a second-generation BTK inhibitor, designed with improved selectivity for BTK over other kinases compared to earlier agents [3].
What is the regulatory status of Calquence?
Calquence has received approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its indicated uses [1][6]. These approvals are based on clinical trial data demonstrating the drug's safety and efficacy [1][6].
What clinical data supports Calquence's use?
The efficacy and safety of Calquence have been established through several clinical trials. For instance, studies like ELEVATE-RR demonstrated non-inferiority in progression-free survival for acalabrutinib compared to ibrutinib in previously treated CLL patients [7]. The ELEVATE-TN trial showed superior progression-free survival for acalabrutinib combined with obinutuzumab versus chlorambucil plus obinutuzumab as a first-line treatment for CLL [7].
What are the patient considerations for Calquence treatment?
Patients considering Calquence should have a thorough discussion with their oncologist about the potential benefits, risks, and treatment schedule [1]. Monitoring for side effects, adherence to the prescribed dosage, and regular follow-up appointments are essential components of Calquence therapy [1].
Sources:
[1] https://www.cancer.gov/drug-dictionary/calquence
[2] https://www.drugbank.ca/drugs/DB12594
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382318
[4] https://drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167941
[6] https://www.ema.europa.eu/en/medicines/human/EPAR/calquence
[7] https://ash.confex.com/ash/2020/webprogram/Paper137374.html